Factors predicting microinvasion in Ductal Carcinoma in situ. 2014

Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
Department of Surgery, School of Medicine, Namik Kemal University, Tekirdag, Turkey E-mail : neslicab@yahoo.com.

BACKGROUND Whether sentinel lymph node biopsy (SLNB) should be performed in patients with pure ductal carcinoma in situ (DCIS) of the breast has been a question of debate over the last decade. The aim of this study was to identify factors associated with microinvasive disease and determine the criteria for performing SLNB in patients with DCIS. METHODS 125 patients with DCIS who underwent surgery between January 2000 and December 2008 were reviewed to identify factors associated with DCIS and DCIS with microinvasion (DCISM). RESULTS 88 patients (70.4%) had pure DCIS and 37 (29.6%) had DCISM. Among 33 DCIS patients who underwent SLNB, one patient (3.3%) was found to have isolated tumor cells in her biopsy, whereas 1 of 14 (37.8%) patients with DCISM had micrometastasis (7.1%). Similarly, of 16 patients (18.2%) with pure DCIS and axillary lymph node dissection (ALND) without SLNB, none had lymph node metastasis. Furthermore, of 20 patients with DCISM and ALND, only one (5%) had metastasis. In multivariate analysis, the presence of comedo necrosis [relative risk (RR)=4.1, 95% confidence interval (CI)=1.6-10.6, P=0.004], and hormone receptor (ER or PR) negativity (RR=4.0, 95%CI=1.5-11, P=0.007), were found to be significantly associated with microinvasion. CONCLUSIONS Our findings suggest patients presenting with a preoperative diagnosis of DCIS associated with comedo necrosis or hormone receptor negativity are more likely to have a microinvasive component in definitive pathology following surgery, and should be considered for SLNB procedure along with patients who will undergo mastectomy due to DCIS.

UI MeSH Term Description Entries
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001940 Breast In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES. Breasts
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002285 Carcinoma, Intraductal, Noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma. Carcinoma, Intraductal,DCIS,Ductal Carcinoma In Situ,Atypical Ductal Hyperplasia,Intraductal Carcinoma, Noninfiltrating,Atypical Ductal Hyperplasias,Carcinoma, Noninfiltrating Intraductal,Carcinomas, Intraductal,Carcinomas, Noninfiltrating Intraductal,Ductal Hyperplasia, Atypical,Ductal Hyperplasias, Atypical,Hyperplasia, Atypical Ductal,Hyperplasias, Atypical Ductal,Intraductal Carcinoma,Intraductal Carcinomas,Intraductal Carcinomas, Noninfiltrating,Noninfiltrating Intraductal Carcinoma,Noninfiltrating Intraductal Carcinomas

Related Publications

Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
August 2003, American journal of surgery,
Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
June 1998, Cancer,
Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
November 2010, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
May 2017, Breast cancer (Tokyo, Japan),
Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
June 1999, Cancer,
Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
December 2012, World journal of surgical oncology,
Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
October 2008, American journal of surgery,
Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
January 2021, Clinical epidemiology,
Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
October 2021, Cancer medicine,
Sibel Ozkan-Gurdal, and Neslihan Cabioglu, and Beyza Ozcinar, and Mahmut Muslumanoglu, and Vahit Ozmen, and Mustafa Kecer, and Ekrem Yavuz, and Abdullah Igci
January 2006, Pathology, research and practice,
Copied contents to your clipboard!